Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Graham, Timothy J ^a   Box, Gary ^b   Tunariu, Nina ^a   Crespo, Mateus ^b   Spinks, Terry J ^a   Miranda, Susana ^b   Attard, Gerhardt ^b   De Bono, Johann ^b   Eccles, Suzanne A ^b   Davies, Faith E ^b   Robinson, Simon P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CABOZANTINIB; MEDRONATE TECHNETIUM TC 99M; ANILIDE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL IMAGING SYSTEM; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BONE GROWTH; BONE MASS; BONE METASTASIS; BONE REMODELING; CANCER GROWTH; CANCER SIZE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CT SPECT SCANNER; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; ELECTRORETINOGRAM; EX VIVO STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOSCLEROSIS; PET-CT SCANNER; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TRABECULAR BONE; TREATMENT RESPONSE; TUMOR ENGRAFTMENT; TUMOR NECROSIS; TUMOR XENOGRAFT; AGED; ANIMAL; BONE TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; LUMINESCENCE; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; SCINTISCANNING; TUMOR VOLUME;

AGED; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE REMODELING; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED NOD; MICE, NUDE; MIDDLE AGED; OSTEOLYSIS; OSTEOSCLEROSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR PROTEIN-TYROSINE KINASES; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898853470     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju033     Document Type: Article

References (38)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s-6249s.
2. Mehra R, Kumar-Sinha C, Lonigro RJ, et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011;17(12):3924-3932.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664.
4. Santini D, Galluzzo S, Zoccoli A, et al. New molecular targets in bone metastases. Cancer Treat Rev. 2010;36(Suppl 3):S6-S10.
5. Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6(10):2609-2617.
6. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011;29(27):3705-3714.
7. Sturge J, Caley M P, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol. 2011;8(6):357-368.
8. Chandra S, Muir C, Silva M, Carr S. Imaging biomarkers in drug development: an overview of opportunities and open issues. J Proteome Res. 2005;4(4):1134-1137.
9. Clamp A, Danson S, Nguyen H, Cole D, Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004;5(10):607-616.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
11. Yakes FM, Chen J, Ta n J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298-2308.
12. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995;147(2):386-396.
13. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60(6):1113-1117.
14. Humphrey PA, Halabi S, Picus J, et al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 2006;4(4):269-274.
15. Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001;61(6):2533-2536.
16. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7(7):1932-1936.
17. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase ii randomized discontinuation trial. J Clin Oncol. 2013;31(4):412-419.
18. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555-1577.
19. Al Nakouzi N, Bawa O, Le Pape A, et al. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer. Neoplasia. 2012;14(5):376-387.
20. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998;17(4):331-336.
21. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644- 648.
22. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11(2):102-125.
23. Hoff BA, Chughtai K, Jeon YH, et al. Multimodality imaging of tumor and bone response in a mouse model of bony metastasis. Transl Oncol. 2012;5(6):415-421.
24. Lee K, Bradley D, Hussain M, et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia. 2007;9(12):1003-1011.
25. Messiou C, Collins DJ, Giles S, et al. Assessing response in bone metas-tases in prostate cancer with diffusion weighted MRI. Eur Radiol. 2011;21(10):2169-2177.
26. Messiou C, Collins DJ, Morgan VA, Desouza NM. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol. 2011;21(8):1713-1718.
27. Padhani AR, Gogbashian A. Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer Imaging. 2011;11(Spec No A):S129-S145.
28. Brenner AI, Koshy J, Morey J, Lin C, DiPoce J. The bone scan. Semin Nucl Med. 2012;42(1):11-26.
29. Holder LE. Clinical radionuclide bone imaging. Radiology. 1990;176(3):607-614.
30. Peller PJ, Ho VB, Kransdorf MJ. Extraosseous Tc-99m MDP uptake: a pathophysiologic approach. Radiographics. 1993;13(4):715-734.
31. Einhorn TA, Vigorita VJ, Aaron A. Localization of technetium-99m meth-ylene diphosphonate in bone using microautoradiography. J Orthop Res. 1986;4(2):180-187.
32. Nemoto R, Nakamura I, Nishijima Y, et al. Serum pyridinoline crosslinks as markers of tumor-induced bone resorption. Br J Urol. 1997;80(2):274-280.
33. Nagae M, Hiraga T, Wakabayashi H, et al. Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone. 2006;39(5):1107-1115.
34. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neuro-chemical reorganization of the spinal cord. Nat Med. 2000;6(5):521-528.
35. Weinfurt K P, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol. 2006;17(6):986v989.
36. Collette L, Burzykowski T, Carroll KJ, et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol. 2005;23(25):6139-6148.
37. Attard G, de Bono JS. Prostate cancer: PSA as an intermediate end point in clinical trials. Nat Rev Urol. 2009;6(9):473-475.
38. Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14(9):2763-2767.